Ge Long Hui A P P·2026-01-05 08:12Core Viewpoint - The company has received approval from the National Medical Products Administration for the clinical trial of its 24-valent pneumococcal polysaccharide conjugate vaccine, which addresses a significant public health issue caused by Streptococcus pneumoniae [1][2] Group 1: Product Development - The 24-valent pneumococcal polysaccharide conjugate vaccine (PCV24) targets the major circulating serotypes of pneumococcus and is designed for use in individuals aged 2 months and older [1] - The vaccine employs a covalent binding method of polysaccharide antigens with protein carriers, utilizing dual carrier technology [1] - The product has completed the development and confirmation of the production process for purified polysaccharides from 24 serotypes and the formulation of the final product [1] Group 2: Market Context - Pneumococcal diseases are a major cause of morbidity and mortality among infants and the elderly in China, with over 100 identified serotypes capable of causing disease [1] - The World Health Organization has classified pneumococcal diseases as a condition that requires "high priority" for vaccine prevention [1] - As of the announcement date, there are no existing products for the 24-valent pneumococcal polysaccharide conjugate vaccine available in domestic or international markets [2]